SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is trending amidst intense retail speculation, primarily fueled by its exceptionally low share float which the community believes could lead to a significant short squeeze. Traders are actively discussing its potential for rapid price appreciation, with some noting recent positive financial indicators and management actions as contributing factors to its anticipated breakout.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending with high anticipation for the January 31, 2026 PDUFA date of its needle-free Anaphylm oral epinephrine film, a key catalyst significantly de-risked by the FDA waiving an Advisory Committee meeting. The community is expressing strong conviction for approval, highlighting Anaphylm's potential to be a market-dominant, game-changing alternative for severe allergic reactions due to its convenience. Despite active debate with short sellers and market fluctuations, many investors are looking towards significant post-approval price appreciation and future growth.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid a dual narrative: China's sanctions, perceived by many as validation of its strategic importance in defense, and the imminent U.S. ban on foreign-made drones. The community is actively discussing how these developments, coupled with anticipated increases in defense budgets for U.S.-made small drones and unmanned surface vessels, could position the company for significant contract awards, despite past concerns over management's communication and tangible revenue delivery.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) experienced a sharp pullback following the CME Group's increase in margin requirements for silver futures, triggering forced liquidations. This move has ignited intense community debate, with many investors citing market manipulation and a disconnect between paper and physical silver prices, particularly in light of impending Chinese export restrictions. Despite the volatility, many bulls are calling this a buying opportunity due to perceived supply shortages and increasing industrial demand, while others anticipate further declines and lament potential 'bag holding.'

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending amidst high anticipation for multiple regulatory catalysts, including upcoming FDA decisions for Tradipitant for motion sickness and Bysanti. The community is actively discussing recent positive Phase 2 data showing Tradipitant's efficacy in mitigating GLP-1 induced nausea, with many speculating this could unlock a massive market and lead to significant stock re-rating or a potential buyout.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical ($RARE) is trending due to a significant sell-off following the unexpected failure of its late-stage setrusumab trial for brittle-bone disease to meet its primary endpoint. This news has sparked a heated community debate, with many investors questioning if the steep stock decline is an overreaction given Ultragenyx's existing portfolio of four approved therapies and multiple upcoming pipeline catalysts. While some see a 'huge opportunity' for a rebound at a deep discount, others remain cautious amid the volatility typical of the biotech sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is actively trending following a significant pullback from recent highs, with community discussion centered on whether this sharp drop is a healthy consolidation or a market-maker-driven "rugpull" fueled by increased margin requirements. While many view it as a buying opportunity in a broader context of a weakening dollar and persistent inflation concerns, others express caution, debating the sustainability of the rally and the potential for further volatility across precious metals.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is trending as the community anticipates a significant silver squeeze, fueled by an impending China export ban and surging industrial demand for AI, EVs, and solar. Investors are increasingly concerned about the divergence between paper and physical silver prices, believing years of manipulation are breaking, positioning PSLV for a substantial, generational bull run as silver gains recognition as a critical global commodity.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings (THH) is trending due to significant price action and high trading volume following its recent IPO, sparking community speculation about a potential short squeeze given its low float. Investors are highlighting its strong return on equity and diversified Japanese lifestyle entertainment business, though some express concerns about its long-term viability.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending as discussions intensify around its near-term regulatory decision for Relacorilant for Cushing's syndrome and the promising trial outcomes for its ovarian cancer and ALS programs. The community anticipates these pipeline advancements will unlock substantial future revenue, positioning the company for significant growth and prompting speculation about a potential short squeeze given its high short interest. This outlook is further supported by updated analyst price targets reflecting optimism about Corcept's expanding therapeutic impact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Gold (NGD) is an Incredible Growth Stock: 3 Reasons Why 

New Gold (NGD) could produce exceptional returns because of its solid growth attributes.

Should You Invest in New Gold (NGD) Based on Bullish Wall Street Views?

According to the average brokerage recommendation (ABR), one should invest in New Gold (NGD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Why the Market Dipped But New Gold (NGD) Gained Today

In the most recent trading session, New Gold (NGD) closed at $9.33, indicating a +2.75% shift from the previous trading day.

Are You Looking for a Top Momentum Pick? Why New Gold (NGD) is a Great Choice

Does New Gold (NGD) have what it takes to be a top stock pick for momentum investors? Let's find out.

New Gold Inc. (NGD) Hit a 52 Week High, Can the Run Continue?

New Gold (NGD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Look Bullish on New Gold (NGD): Should You Buy?

Based on the average brokerage recommendation (ABR), New Gold (NGD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Arkema & Semcorp Form Alliance to Advance Battery Separator Development 

ARKAY teams up with Semcorp to drive faster innovation and global deployment of high-performance battery separators across key markets. 

New Gold (NGD) Is Up 23.70% in One Week: What You Should Know 

Can AngloGold Ashanti's Augusta Buyout Aid Further Growth? 

AU's Augusta Gold buyout expands its Nevada footprint with the Reward project and added deposits to fuel growth.


Here is Why Growth Investors Should Buy New Gold (NGD) Now 

New Gold (NGD) possesses solid growth attributes, which could help it handily outperform the market.

New Gold, Inc. is a gold mining company, which engages in the operation, development, and exploration of mineral properties. Its portfolio includes Rainy River, New Afton, and Cerro San Pedro. The company was founded on January 31, 1980 and is headquartered in Toronto, Canada.

Current Price	$8.89
Prev Close	$9.33
Open	$8.86
Dividend Yield	0.00%
50-Day Moving Average	$7.53
Beta	0.78
Avg. Volume	27.14M
PE Ratio	29.63

52-Week High	$9.59
52-Week Low	$2.43
Market Capitalization	$7.39B
EPS (Annual)	$0.1364
Price to Book	5.96
Revenue Per Employee	$566,894.83
Enterprise Value/EBITDA	N/A

NGD
New Gold Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NGD News

NGDNew Gold Inc